Chordia Therapeutics (190A) · RiskFirst stated

Risk of Failing to Secure Intellectual Property Rights Due to the End of Joint Research Agreements with Universities and Public Research Institutions

First written in FY2025. . Latest entry: FY2025.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Risk of dependence on joint R&D counterparties and termination of agreementsA theme 16 companies write about · 19 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 2 of 6 companies on the "Worse" side.

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 16 companies compared. The sentences above are computed from all 16.

Full recordFilings, disclosures and news, newest first

FY2025First statedAnnual report
「If the terms of a joint research agreement relating to inventions or patent rights for which a university or research institution is the applicant are changed in the future, or if the agreement ends due to expiration, termination or other reasons, we may be unable to secure the relevant intellectual property rights, which could affect our business.」
The company separately identified the risk of losing exclusive rights of implementation and other rights to the results of joint research with universities and public research institutions due to contract changes, expiration or termination.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

Chordia Therapeutics's next results are scheduled for 2026-10-15. Read the earnings preview

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.